Opinion|Videos|August 15, 2024
Novel Treatment and Diagnostics for Dry Eye
Experts discuss strategies for making dry eye care an appealing practice option for optometry students and supporting their success in this specialized field.
Advertisement
Episodes in this series
0:55 Treatment Advanced
5:00 Treating Demodex
13:40 Semifluorinated Alkanes
16:15 Treatment Selection
22:10 New Research Targets
28:50 AI in Diagnostics
Advertisement
Related to this article
Hematology in September 2026: ASH raises ferritin thresholds for iron deficiency, plus marstacimab in hemophilia and curative SCD care.
Strong recommendations cover carvedilol or banding for varices, semiannual HCC surveillance, vaccines, and smoking cessation.
April Armstrong, MD, MPH, discusses 1-year RELIEVE-AD-PEDs data on rapid, sustained dupilumab disease control in adolescents with atopic dermatitis.
Physicians and patients cited perceived mild severity as the top reason for leaving HAE attacks untreated in a recent Adelphi survey.
Nephrology in September 2026: FDA approves finerenone for CKD in T1D and obinutuzumab for nephrotic syndrome, plus ORIGIN 3 IgAN data.
Gastroenterology in September 2026: SPY003 phase 2 data in UC, antifungal therapy in IBD, and EPI prevalence in chronic pancreatitis.
Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.
Centanafadine's ADHD approval, the MDMA NDA resubmission, DT120 phase 3 wins, and the FDA psychedelic hearing headline Q3 2026 psychiatry news.
Advertisement
Advertisement
Trending on HCPLive
1
Ritlecitinib Stabilizes Vitiligo in Tranquillo Trial, With Iltefat Hamzavi, MD
2
Advances in Treating High-Impact Psoriasis from EADV 2026
3
FDA Updates Sotatercept Label, ERS Releases PAH Guidelines to Include HYPERION Data
4
From Injectable to Oral: Optimal Durable Clearance Across the IL-23 Class
5